Cargando…

Toripalimab in advanced biliary tract cancer

Gemcitabine combined with platinum/fluorouracil drugs is the standard first-line treatment for advanced biliary tract cancers (BTCs). We explored the safety and efficacy of toripalimab plus gemcitabine and S-1 (GS) as the first-line treatment for advanced BTCs. At a one-sided significance level of 0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Wei, Wang, Yueqi, Yu, Yiyi, Li, Qian, Wang, Yan, Zhang, Chenlu, Xu, Xiaojing, Guo, Xi, Dong, Yu, Cui, Yuehong, Hao, Qing, Huang, Lujia, Liu, Houbao, Liu, Tianshu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125659/ https://www.ncbi.nlm.nih.gov/pubmed/35615603 http://dx.doi.org/10.1016/j.xinn.2022.100255

Ejemplares similares

Landscape of distant metastasis mode and current chemotherapy efficacy of the advanced biliary tract cancer in the United States, 2010‐2016
por: Wang, Jie, et al.
Publicado: (2019)

Laparoscopic common bile duct exploration in patients with previous abdominal biliary tract operations
por: Li, Min, et al.
Publicado: (2020)

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients
por: Bo, Xiaobo, et al.
Publicado: (2018)

Asparaginyl endopeptidase promotes the invasion and metastasis of gastric cancer through modulating epithelial-to-mesenchymal transition
por: Cui, Yuehong, et al.
Publicado: (2016)

Effect of Immune Checkpoint Inhibitors Plus Chemotherapy on Advanced Gastric Cancer Patients with Elevated Serum AFP or Hepatoid Adenocarcinoma
por: Li, Wei, et al.
Publicado: (2020)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Phase I study of adjuvant chemotherapy with nab‐paclitaxel and S‐1 for stage III Lauren's diffuse‐type gastric cancer after D2 resection (NORDICA study)
por: Cui, Yuehong, et al.
Publicado: (2022)

Prognosis of Adjuvant SOX vs XELOX Chemotherapy for Gastric Cancer After D2 Gastrectomy in Chinese Patients
por: Yu, Shan, et al.
Publicado: (2020)

Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study
por: Li, Qian, et al.
Publicado: (2016)

Response to toripalimab combined with radiotherapy in advanced non-small cell lung cancer-not otherwise specified: A case report
por: Jin, Yonglong, et al.
Publicado: (2021)

Tumor‐infiltrating neutrophils predict prognosis and adjuvant chemotherapeutic benefit in patients with biliary cancer
por: Wang, Jie, et al.
Publicado: (2018)

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
por: Zan, Ning, et al.
Publicado: (2022)

Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study
por: Zhang, Lingyun, et al.
Publicado: (2022)

Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study
por: Li, Wei, et al.
Publicado: (2019)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
por: Zhang, Lin, et al.
Publicado: (2022)

Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer
por: Zhao, Qing, et al.
Publicado: (2015)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Efficacy and Safety of Regorafenib Combined with Toripalimab in the Third-Line and beyond Treatment of Advanced Colorectal Cancer
por: Yu, Wei, et al.
Publicado: (2021)

FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc
por: Yu, Yiyi, et al.
Publicado: (2016)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients
por: Xu, Xiaojing, et al.
Publicado: (2020)

Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen
por: Tang, Cheng, et al.
Publicado: (2018)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer
por: Wang, Hao, et al.
Publicado: (2023)

Epithelioid hemangioendothelioma of the retroperitoneal giant type treated with Toripalimab: A case report
por: Bu, Yuqing, et al.
Publicado: (2023)

Effectiveness and Safety of Toripalimab Combination Therapies for Patients With Chemo-Resistant Choriocarcinoma
por: Liu, Xiaomei, et al.
Publicado: (2022)

Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach
por: Zhu, Mengxuan, et al.
Publicado: (2022)

Mining the role of angiopoietin‐like protein family in gastric cancer and seeking potential therapeutic targets by integrative bioinformatics analysis
por: Tang, Cheng, et al.
Publicado: (2020)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Radiofrequency ablation combined with toripalimab for recurrent hepatocellular carcinoma: A prospective controlled trial
por: Wen, Zhenyu, et al.
Publicado: (2023)

FOXO3a promotes gastric cancer cell migration and invasion through the induction of cathepsin L
por: Yu, Shan, et al.
Publicado: (2016)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
por: Tao, Ye, et al.
Publicado: (2023)

Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO‐CLASSIC Study
por: Yu, Yiyi, et al.
Publicado: (2019)

Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review
por: Xu, Xiaojing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ri3p1rndn11pbs39n8bbgrlkcu